Overview

Most hearing loss is caused by the death or damage to the sensory cells in the cochlea. This is called sensorineural hearing loss, and this makes up an estimated 90% of all hearing loss in humans. These sensory cells are of two types, both required for hearing; hair cells and auditory neurons. Both types are very easy to damage through exposure to noise, certain chemicals, or just as a natural consequence of ageing. These cells cannot be repaired or naturally regenerated in humans. They develop in utero: you are born with a compliment that you must retain for your entire life. If you lose them or they are damaged, you lose hearing function and therefore progressive loss results in progressive deafness.

There are no current treatments for hearing loss related to loss of auditory neurons. Hair cell damage can be partially circumvented by the use of hearing aids and cochlear implants, there are no treatment options that target auditory neuron loss. Hearing aids are sound amplifiers that detect sound and amplify frequencies which are useful for the perception of human speech. Cochlear implants are devices which detect the sound from the environment, convert it to electrical signals, and then send a signal to the internal electrode array of the implant, effectively bypassing the damaged hair cells to directly stimulate the auditory neurons. However, if the auditory neurons are lost or damaged, then these medical devices will not work well because you need the auditory neuron population to send the sound signal from the cochlea to the brain.

People with hearing loss related to auditory neuron function are particularly badly served by current healthcare solutions. This is particularly problematic as the most common form of hearing loss, presbycusis (also known as age-related hearing loss), auditory neuron loss has been shown to proceed hair cell loss. Published research¹ has shown that by 60 years of age, average loss of auditory neurons is around 46%. The first treatment in Rinri’s pipeline is focused on repairing damage to the auditory neurons, and has the potential to make a difference to the millions of people with age-related hearing loss, or more rare conditions such as auditory neuropathy.

¹ Wu, P.Z. et al. (2019) “Primary neural degeneration in the human cochlea: Evidence for hidden hearing loss in the aging ear,” Neuroscience, 407, pp. 8–20. Available at: https://doi.org/10.1016/j.neuroscience.2018.07.053.

Statistics, Facts & Figures

The WHO estimates that, currently, more than 5% of the world’s population (approximately 430 million people) has disabling hearing loss1

In the US, approximately 65 million people are affected by hearing loss; in Europe it is about 34 million2

There is no approved pharmacological treatment for sensorineural hearing loss despite causing 90% of hearing loss in adults3

In the most common form of sensorineural hearing loss, age related hearing loss (presbycusis), the auditory neurons stop working before the hair cells do

Auditory Neuropathy Spectrum Disorder, where the hair cells work but the auditory neurons do not, affects 10% of people with sensorineural hearing loss

5% of people who could benefit from a cochlear implant have one5

In the UK, untreated hearing loss costs around £25.5 billion each year7 in lost productivity and unemployment

6.7 million could benefit from hearing aids, but only about 2 million people use them6

About 12,000 people in the UK use cochlear implants4

The WHO estimates that, currently, more than 5% of the world’s population (approximately 430 million people) has disabling hearing loss1

In the US, approximately 65 million people are affected by hearing loss; in Europe it is about 34 million2

There is no approved pharmacological treatment for sensorineural hearing loss despite causing 90% of hearing loss in adults3

75% of the 90% suffer damage to the hair cells

25% of the 90% have death or damage to the auditory neurons

5% of people who could benefit from a cochlear implant have one5

In the UK, untreated hearing loss costs around £25.5 billion each year7 in lost productivity and unemployment

6.7 million could benefit from hearing aids, but only about 2 million people use them6

About 12,000 people in the UK use cochlear implants4

In 2018, less than 1% of the total public and charity investment in medical research was spent on hearing research. That adds up to just 83p spent for every person affected8

Patient Perspective

The perspective of people with hearing loss

Rinri is working closely with people with hearing loss and their family members to inform the work that we are carrying out. An important part of this is understanding their perspectives and needs as well as their thoughts on Rinri’s cell therapy. Discussions with people with hearing loss have revealed that there is considerable demand and need for a treatment that restores natural hearing without the need for hearing devices such as hearing aids and cochlear implants. Specifically, they have expressed that hearing devices are “very limited” and that “normal hearing is totally different from a cochlear implant and would be wonderful…and unbelievable”. They feel that it “takes an awful lot of work to hear and recognise sounds again” with a cochlear implant. Rinri have found that people with hearing loss would like to have access to the full range and complexity of sound, that they would like to experience the joys of music and participate in group conversations; these are benefits that not even the very best hearing devices can guarantee. In addition, parents of children with hearing loss have expressed that a hearing restoration cell therapy would be “amazing” and is the “ultimate goal” for their children, especially since we live in a hearing world. They have further highlighted that natural hearing would “massively enhance life” for children who have additional needs.